menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Penn Medicine Studies Unlock New Insights into Gene Therapy

ReachMD Healthcare Image
11/16/2023
pennmedicine.org

PHILADELPHIA –Gene therapy adeno-associated viruses (AAVs)—viruses that can be engineered to deliver DNA to target cells—are unlikely to cause cancer-triggering insertions in humans or monkeys and may contribute to long-term efficacy, according to new research from the University of Pennsylvania’s Gene Therapy Program (GTP). AAVs that are used to deliver gene therapies sometimes end up being inserted into chromosomal DNA, which has led to concerns that such insertions could disrupt the host genome, potentially causing cellular dysfunction or the development of cancer. However, two large companion studies in non-human primates indicate that vector integrations in primate liver following AAV gene therapy may be an important mechanism for achieving durable expression and are unlikely to induce cancer mutations in humans aligning with the low-risk integration patterns observed in natural non-pathogenic AAV infections.

Virus-delivered gene therapies have been investigated for several decades, with eight having been approved by the U.S. Food and Drug Administration for conditions including hemophilia and muscular dystrophy. Most use AAVs to deliver their gene payloads. The two new studies, both published today in Nature Biotechnology and Human Gene Therapy, amount to the most comprehensive exploration of AAV chromosomal integrations in primates to date and carry important implications for the safety profile and long-term efficacy of AAV-based gene therapies.

Viruses evolved to break into cells, and gene therapy researchers have long viewed them as the go-to carriers or “vectors” for therapeutic transgenes. AAVs are the most commonly used viral vectors for gene therapies because they can enter both dividing and non-dividing cells, don’t cause viral illness in humans, and usually don’t trigger an immune response—which would swiftly degrade their therapeutic impact.

AAVs and the therapeutic transgenes they can carry normally exist “episomally”—free-floating in the cell nucleus and not integrated into chromosomal DNA. However, scientists now recognize that engineered AAVs used for gene therapies do sometimes end up in chromosomal DNA, perhaps mainly as a result of DNA repair processes that inadvertently stitch them into the genome. Some studies of liver-directed AAV gene therapies in mice, especially newborn mice, have found that these insertions can trigger liver cancer by disrupting cancer-blocking regulatory elements in the genome. Whether this is likely to happen in humans and other primates has been unclear.

In the Human Gene Therapy study, Penn researchers examined tissue samples, mostly liver samples, from 86 macaque monkeys that had been treated with AAV-based gene therapies in preclinical tests, and 253 macaques and humans that had never been exposed to engineered AAVs. They found that the engineered AAVs in the gene therapy recipients, and endemic natural (“wild-type”) AAVs in the other group, were inserted at low rates in mostly random distributions across the genome with a low risk for expansion, even in a monkey 15 years after treatment.

In the Nature Biotechnology study, Wilson’s team followed 12 macaques for over 2 years after they received AAV-based gene therapies targeting liver cells. They found the presence of complex structures of AAV genomes existing outside of the chromosome that persist but appear to be rapidly inactivated soon after vector delivery. Integrated forms of vector DNA appeared at lower frequencies consistent with the number of cells that stably express the transgene suggesting that durability of AAV gene therapy in primate liver may be due to integrated forms of the vector. Once again, they found a low frequency of AAV vector sequences embedded in chromosomal DNA, at varying sites across the genomes. None of these sites were close to genes whose disruption has been linked to liver cancer, and there was no evidence of marked clonal expansion during the years of follow-up.

“These studies inform new approaches for improving liver gene therapy that focus more on expression rather than delivery,” said study senior authorJames M. Wilson, MD, PhD, director of the Gene Therapy Program, Rose H. Weiss Professor and Director of the Orphan Disease Center, and professor in the Departments of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. “Our data also highlight the potential advantages of genome editing for liver in which insertions are directed to safe harbor regions of the chromosome above the background of more widely distributed integrations that occur with vector alone.”

The Human Gene Therapy study was supported by funds from the Gene Therapy Program at Penn Medicine. The Nature Biotechnology study was supported by Amicus Therapeutics, Passage Bio, and Ultragenyx.

Penn Financial Disclosures
Dr. Wilson is a Penn faculty member as well as a scientific collaborator with Amicus, Passage Bio, and Ultragenyx.  As such, his laboratory at Penn has received sponsored research funding from all of these companies, and as an inventor of certain Penn intellectual property that is licensed to these companies, Dr. Wilson may receive additional financial benefits in the future. The University of Pennsylvania has licensed intellectual property to all three of these companies that have resulted, and may continue to result in future financial returns to Penn.  Dr. Wilson is also a consultant and co-founder of Passage Bio, and he holds an equity stake in the company.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Facebook Comments

Schedule3 Mar 2024